Pirfenidone treatment for idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of safety
R. Du Bois, C. Albera, W. Bradford, U. Costabel, T. King, S. Sahn, J. Szwarcberg, D. Valeyre, P. Noble (Denver, Brisbane, San Francisco, Charleston, Durham, United States Of America; Turin, Italy; Essen, Germany; Paris, France)
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Session: Idiopathic pulmonary fibrosis: concepts and mechanisms
Session type: Oral Presentation
Number: 2823
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Du Bois, C. Albera, W. Bradford, U. Costabel, T. King, S. Sahn, J. Szwarcberg, D. Valeyre, P. Noble (Denver, Brisbane, San Francisco, Charleston, Durham, United States Of America; Turin, Italy; Essen, Germany; Paris, France). Pirfenidone treatment for idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of safety. Eur Respir J 2009; 34: Suppl. 53, 2823
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: